Effectiveness of Transcutanclus electrical acupoint stimulation combined with acupoint application on radiation-induced xerostomia in patients with oral cancer

Phase 4

• Conditions: Oral cancer

• Registration Number: ITMCTR2200006467
• Lead Sponsor: Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Oral cancer with radiation and histological confirmation.Adult > 18 years of age, without tumor recurrence.
2. with an anticipated survival of more than six months and Karnofsky performance status = 60.
3. Able to give informed consent and ethics committee approval. Patients communicate normally and (verbally or in writing).
4. Planned intensity-modulated radiation therapy (IMRT), with or without concurrent chemotherapy or induction treatment, no parotid duct ligation or excision, and best attempts to minimize the bilateral parotid. One parotid gland receives an average dosage of less than 20 Gy, while both parotid glands get an average dose of less than 25 Gy.

Exclusion Criteria

1. History of xerostomia prior to head and neck radiation therapy, Sj?gren's disease, salivary fistula, or another underlying systemic illness is known to cause xerostomia.
2. Patients who do not want to participate in this experiment or those who receive therapy using a different approach and are unable to follow the prescribed course of treatment
3. History of communication disorders, psychiatric disorders, epilepsy, and cardiovascular disease. with a cardiac pacemaker.
pregnant women.
4. lower extremity disorders that prevent the selection of acupuncture points and allergies to acupuncture point patches.
5. If a patient was using any salivary substitute, they were asked to refrain from using the product for at least 24 hours prior to saliva and questionnaire data collection.
6. currently taking amifostine, cholinergic agonist medications (pilocarpine, cevimeline), or other
medications are known to affect salivary function.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Xerostomia Questionnaire(XQ);

Secondary Outcome Measures

Name	Time	Method
salivary flow rate;QLQH&N35;